Beneficial effects of upadacitinib on a subgroup of patients with atopic dermatitis and hidradenitis suppurativa: a multicenter, real-world retrospective study - PubMed
5 hours ago
- #hidradenitis suppurativa
- #atopic dermatitis
- #upadacitinib
- Upadacitinib showed beneficial effects on patients with both atopic dermatitis (AD) and hidradenitis suppurativa (HS).
- The study included 195 AD patients, with 3.6% also having HS. Significant improvements in HS symptoms were observed as early as 4 weeks into treatment.
- Mean IHS4 scores decreased from 6.9 at baseline to 0.2 by week 32, indicating substantial symptom relief.
- HiSCR and IHS4-S5 response rates were high, with most patients achieving these benchmarks by week 16.
- The findings suggest upadacitinib could be an effective treatment for patients suffering from both AD and HS.